Results: Seventy-five patients with a median age of 60 years (range from 23 to 79 years) were treated with a combination of surgery (n=66), radiotherapy (adjuvant for 64 patients and exclusive for 8 patients) and temozolomide based chemotherapy (n= 58). Median follow-up was 12 months (range from 2 to 71 months). Two-year overall survival (OS) and disease free survival rates were 12% (95% CI: 4-20%) and 2% (95% IC: 0-6%), respectively. The median OS was 13 months. Treatment at recurrence consisted of chemotherapy (n=38) (bevazicumab for 18 patients, resumed temozolomide for 10 patients), salvage surgery (n = 8) and radiochemotherapy (n= 1). In univariate analysis, younger age, high total dose of radiotherapy, long time to recurrence and treatment at recurrence increased significantly OS. In multivariate analysis, high total dose of radiotherapy (HR = 0.97, p = 0.007) and treatment at recurrence (HR = 0.28 p<0.001) were favourable prognostic factor of OS. Purpose or Objective: JCOG0211 study demonstrated that the 5-year local control, 5-y OS and 5-y PFS of patients treated with RT-DeVIC were 94, 70 and 63%, respectively. NKEA project (UMIN000015491) conducted a multiinstitutional retrospective study to clarify the changing current practice of the treatment for Extranodal natural killer(NK)/T-cell lymphoma nasal type(ENKL) over the first decade of this century in Japan, reviewing detailed information on treatment, clinical features and prognosis of patients with ENKL. The aim of this sub-study is to investigate the relationship between local failure patterns and radiation therapy before and after JCOG0211 study.
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The multi-institutional retrospective study of radiation therapy for NK/T-cell lymphoma in Japan Purpose or Objective: JCOG0211 study demonstrated that the 5-year local control, 5-y OS and 5-y PFS of patients treated with RT-DeVIC were 94, 70 and 63%, respectively. NKEA project (UMIN000015491) conducted a multiinstitutional retrospective study to clarify the changing current practice of the treatment for Extranodal natural killer(NK)/T-cell lymphoma nasal type(ENKL) over the first decade of this century in Japan, reviewing detailed information on treatment, clinical features and prognosis of patients with ENKL. The aim of this sub-study is to investigate the relationship between local failure patterns and radiation therapy before and after JCOG0211 study.
Material and Methods:
Selection criteria of NKEA survey are newly pathologically diagnosed ENKL, any stage, and any type of treatment and treated from 2000 to 2013. From 32 institutions, more than 384 data of patients with ENKL have been registering in the NKEA project database. Of them, radiation therapy (RT) data, focusing on CTV setting, of 233 patients with localized nasal ENKL were evaluated with the JROSG-lymphoma committee.
Results:
The baseline patients characteristics were followings, median age was 58 years old (range 18-88), male dominant (2:1), stage I/II=162/66(2.4:1). The median dose of RT was 50 Gy (range 9-60), delivering median 25 (range 3-33) fractionation over 37 (range 9-106) days. The 3D-CRT (CT based RT planning) was applied in 88% of patients and IMRT in 3%, using shrinking technique; 70%. RT was interrupted with 15% of patients due to hematological and mucosal toxicities. After JCOG0211 study, 49% of RT was designed according to JCOG0211 RT protocol, while 80% or more were not compliant RT protocol before/during JCOG0211. The local control was 74% for all population, 88% of local control rate was observed in patients treated with RT compliant with JCOG0211 RT protocol (extended RT), while 70% in patients not compliant with JCOG RT protocol (small field/limited RT). Based on the results of RT-QA review; we would like proposed the CTV guideline for IMRT/VMAT.
Conclusion:
A multi-institutional retrospective survey after prospective clinical trial is important to review how the results of trial influence on the community standard practice of the treatment for rare lymphoma, and observance of radiation therapy guidance. The extended RT had higher local control rate than small limited RT.
PO-0663
Treatment result of primary thyroid lymphoma; a single institute experience N. Yoshikawa
